Marc Stapley Sells 6,250 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) Director Marc Stapley sold 6,250 shares of the stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now owns 34,076 shares of the company’s stock, valued at $4,291,190.68. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Price Performance

GKOS stock opened at $130.00 on Thursday. The company has a market capitalization of $6.55 billion, a P/E ratio of -45.14 and a beta of 1.05. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.68 and a current ratio of 5.48. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $130.13. The business has a 50-day simple moving average of $119.36 and a two-hundred day simple moving average of $105.79.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). The business had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The company’s quarterly revenue was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.55) EPS. Research analysts expect that Glaukos Co. will post -2.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Glaukos by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock worth $500,576,000 after buying an additional 72,159 shares in the last quarter. Brown Capital Management LLC lifted its position in shares of Glaukos by 3.4% during the 4th quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock worth $214,448,000 after buying an additional 89,420 shares in the last quarter. Fred Alger Management LLC lifted its position in shares of Glaukos by 3.8% during the 2nd quarter. Fred Alger Management LLC now owns 1,278,723 shares of the medical instruments supplier’s stock worth $151,337,000 after buying an additional 47,308 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Glaukos by 43.9% during the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock worth $144,483,000 after buying an additional 372,180 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Glaukos by 3.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock worth $73,412,000 after buying an additional 31,213 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

GKOS has been the subject of a number of recent analyst reports. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Truist Financial restated a “buy” rating and issued a $145.00 target price (up from $141.00) on shares of Glaukos in a research note on Thursday, August 1st. Stifel Nicolaus raised their target price on Glaukos from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th. Finally, Morgan Stanley raised their target price on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $127.73.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.